273 related articles for article (PubMed ID: 20078611)
41. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients.
Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L
Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356
[TBL] [Abstract][Full Text] [Related]
42. [Pharmacology of mycophenolate mofetil: recent data and clinical consequences].
Thervet E; Anglicheau D; Legendre C
Nephrologie; 2001; 22(7):331-7. PubMed ID: 11817210
[TBL] [Abstract][Full Text] [Related]
43. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes.
Jagodzinski P; Lizakowski S; Smolenski RT; Slominska EM; Goldsmith D; Simmonds HA; Rutkowski B
Clin Sci (Lond); 2004 Jul; 107(1):69-74. PubMed ID: 14723603
[TBL] [Abstract][Full Text] [Related]
44. Assessment of mycophenolic acid-induced immunosuppression: a new approach.
Millan O; Oppenheimer F; Brunet M; Vilardell J; Rojo I; Vives J; Martorell J
Clin Chem; 2000 Sep; 46(9):1376-83. PubMed ID: 10973868
[TBL] [Abstract][Full Text] [Related]
45. Lymphocyte activation and correlation with IMPDH activity under therapy with mycophenolate mofetil.
Devyatko E; Dunkler D; Bohdjalian A; Zuckermann A; Grimm M; Muehlbacher F; Weigel G
Clin Chim Acta; 2008 Aug; 394(1-2):67-71. PubMed ID: 18474232
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.
Li H; Mager DE; Sandmaier BM; Storer BE; Boeckh MJ; Bemer MJ; Phillips BR; Risler LJ; McCune JS
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1121-9. PubMed ID: 24727337
[TBL] [Abstract][Full Text] [Related]
47. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
Allison AC; Eugui EM
Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
[TBL] [Abstract][Full Text] [Related]
48. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
Vethe NT; Bergan S
Ther Drug Monit; 2006 Oct; 28(5):608-13. PubMed ID: 17038874
[TBL] [Abstract][Full Text] [Related]
49. [Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent].
Yashima Y; Ohgane T
Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):131-7. PubMed ID: 11233304
[TBL] [Abstract][Full Text] [Related]
50. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
51. Mycophenolate mofetil--clinical and experimental experience.
Pirsch JD; Sollinger HW
Ther Drug Monit; 1996 Aug; 18(4):357-61. PubMed ID: 8857550
[TBL] [Abstract][Full Text] [Related]
52. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation.
van Gelder T; Shaw LM
Transplantation; 2005 Oct; 80(2 Suppl):S244-53. PubMed ID: 16251857
[TBL] [Abstract][Full Text] [Related]
53. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome.
Shah S; Harwood SM; Döhler B; Opelz G; Yaqoob MM
Transplantation; 2012 Sep; 94(5):486-91. PubMed ID: 22960765
[TBL] [Abstract][Full Text] [Related]
54. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals.
Vethe NT; Bremer S; Rootwelt H; Bergan S
Ther Drug Monit; 2008 Dec; 30(6):647-55. PubMed ID: 18806697
[TBL] [Abstract][Full Text] [Related]
56. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
[TBL] [Abstract][Full Text] [Related]
57. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.
Kofler S; Wolf C; Shvets N; Sisic Z; Müller T; Behr J; Sohn HY; Vogeser M; Shipkova M; Meiser B; Steinbeck G; Reichart B; Kaczmarek I
J Heart Lung Transplant; 2011 May; 30(5):565-71. PubMed ID: 21256049
[TBL] [Abstract][Full Text] [Related]
58. Expression of IMPDH1 is regulated in response to mycophenolate concentration.
Bremer S; Vethe NT; Rootwelt H; Bergan S
Int Immunopharmacol; 2009 Feb; 9(2):173-80. PubMed ID: 19010451
[TBL] [Abstract][Full Text] [Related]
59. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
[TBL] [Abstract][Full Text] [Related]
60. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study.
Bremer S; Vethe NT; Rootwelt H; Jørgensen PF; Stenstrøm J; Holdaas H; Midtvedt K; Bergan S
J Transl Med; 2009 Jul; 7():64. PubMed ID: 19635156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
